5 Best Immunology Stocks to Invest In

4. Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Number of Hedge Fund Holders: 30 

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a biopharmaceutical company that engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. On December 6, Celldex Therapeutics, Inc announced new data from the company’s open-label Phase 1b clinical trial of barzolvolimab in patients with antihistamine refractory chronic inducible urticaria. Barzolvolimab is a humanized monoclonal antibody.

Among the hedge funds being tracked by Insider Monkey, Boston-based investment firm RA Capital Management is a leading shareholder in Celldex Therapeutics, Inc. (NASDAQ:CLDX) with 2 million shares worth more than $58.3 million.